Výsledky vyhledávání - "S, Mavoungou"

Akademický článek

Leflunomide for BKvirus: Report of Seven Kidney-Transplanted Children

Autor: M Launay, V Baudouin, R Guillemain, A Maisin, H Flodrops, E Douez, S Mavoungou, V Jullien, E Billaud

Publikováno v: International Journal of Organ Transplantation Medicine, Vol 9, Iss 4 (2018)

Background: Leflunomide is an immunosuppressive agent commercialized for treatment of rheumatoid arthritis. Because of its immunosuppressive and possible antiviral properties, leflunomide has been evaluated in some case series of BKVAN with favorable

Externí odkaz: https://doaj.org/article/2c4cedc6edeb4dfb99d58c23ce65044c

Zobrazit plný text záznamu

Guidelines for the management of chronic spontaneous urticaria: recommendations supported by the Centre of Evidence of the French Society of Dermatology

Autor: M.‐H. Jegou, Bernard Guillot, Marie Beylot-Barry, Annabel Maruani, Stéphane Munck, S. Mavoungou, Hélène Cornillier, Bruno Giraudeau, G. d’Acremont, B.‐N. Pham, Olivier Chosidow, A.‐P. Jonville‐Bera, F. Hacard

Publikováno v: The British Journal of Dermatology
British Journal of Dermatology
British Journal of Dermatology, Wiley, 2021, 185 (3), pp.658-660. ⟨10.1111/bjd.20415⟩
British Journal of Dermatology, 2021, 185 (3), pp.658-660. ⟨10.1111/bjd.20415⟩

Chronic spontaneous urticaria (CSU) is an inflammatory disease characterised by spontaneous wheals or angioedema for more than 6 weeks. The natural history of the disease is resolution within several months or years, and treatment is necessary to lim

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6920c37f8acda977b50eff5d0434bf03
http://europepmc.org/articles/PMC8457139

Zobrazit plný text záznamu

Simulation de la part de marché potentielle ambulatoire du rituximab et trastuzumab en 2012–2013 et 2017

Autor: C. Le Bihan-Benjamin, Philippe-Jean Bousquet, M. Rocchi, S. Mavoungou

Publikováno v: Revue d'Épidémiologie et de Santé Publique. 67:S188

Introduction Le trastuzumab (Herceptin®) et rituximab (Mabthera®) sont administres a l’hopital par voie intraveineuse (IV) ou sous-cutanee (SC). Cette derniere est disponible depuis 2014 (trastuzumab) et 2015 (rituximab). Nous supposons qu’elle

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b96b348df84c5b7be22843f976b0b31c
https://doi.org/10.1016/j.respe.2019.04.045

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání